Loading...

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrophages, and dendritic cells. Following its administration, a p...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatr Dis Treat
Main Authors: Babij, Rachel, Perumal, Jai S
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2015
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4445870/
https://ncbi.nlm.nih.gov/pubmed/26056453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S60518
Tags: Add Tag
No Tags, Be the first to tag this record!